[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100330707":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":39,"interventions":52,"overallOfficials":60,"centralContacts":74,"locations":25,"responsibleParty":82,"collaborators":85,"id":88,"slug":25,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":25,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":115,"whyStopped":25,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":25},{"fullName":5,"class":6},"Università degli Studi dell'Insubria","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":25,"otherOutcomes":25},[9,13,17,21],{"measure":10,"description":11,"timeFrame":12},"Gestational diabetes prevalence","Gestational diabetes prevalence: number of women that develop gestational diabetes diagnosed based on oral glucose tolerance test (OGTT) cut-off (92 - 180 - 153 mg\u002Fdl).","During pregnancy at 16-18 week or 24-28 weeks as recommended",{"measure":14,"description":15,"timeFrame":16},"Preeclampsia prevalence","Preeclampsia prevalence: number of women that develop preeclampsia diagnosed based on blood pressure higher than 140\u002F90 mmHg after 20 week of gestation plus 24h proteinuria higher that 300mg.","During pregnancy after the 20 week of gestation",{"measure":18,"description":19,"timeFrame":20},"Birth weight","gr","At delivery.",{"measure":22,"description":23,"timeFrame":24},"Weight gain in pregnancy","Kg","Change in weight before pregnancy and at the 38 week of gestation",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":25,"timePerspective":25,"maskingInfo":31},"RANDOMIZED","PARALLEL","Randomized multi centre double-blind controlled trial","TREATMENT",{"masking":32,"maskingDescription":33,"whoMasked":34},"QUADRUPLE","The patients, care provides, investigators and outcome assessors are blinded for the treatment: Inositol + Folic acid versus Folic acid alone. The treatment allocation is identified by code number before the study start, and will be revealed only after data analysis.",[35,36,37,38],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[40,46],{"label":41,"type":42,"description":43,"interventionNames":44},"Inositol + Folic acid","EXPERIMENTAL","Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Inositol (Myo-inositol and D-chiro-inositol at 40:1 ratio) plus Folic acid before spontaneous conception until delivery.",[45],"Dietary Supplement: Inositol + Folic acid",{"label":47,"type":48,"description":49,"interventionNames":50},"Folic acid","PLACEBO_COMPARATOR","Couples with PCOS infertile women, diagnosed according to the Rotterdam criteria, who access infertility center with conception desire. These women will receive oral supplementation with Folic acid before spontaneous conception until delivery.",[51],"Dietary Supplement: Folic acid",[53,57],{"type":54,"name":41,"description":55,"armGroupLabels":56,"otherNames":25},"DIETARY_SUPPLEMENT","Daily oral supplementation before spontaneous conception until delivery:\n\nMyo-Inositol: 1100 mg D-chiro-inositol: 27.6 mg Folic acid: 400 mcg",[41],{"type":54,"name":47,"description":58,"armGroupLabels":59,"otherNames":25},"Daily oral supplementation before spontaneous conception until delivery:\n\nFolic acid: 400 mcg",[47],[61,64,67,70,72],{"name":62,"affiliation":5,"role":63},"Antonio Simone Laganà, M.D.","PRINCIPAL_INVESTIGATOR",{"name":65,"affiliation":66,"role":63},"Simone Garzon, M.D.","Univerisity of Verona",{"name":68,"affiliation":5,"role":69},"Fabio Ghezzi, M.D.","STUDY_CHAIR",{"name":71,"affiliation":66,"role":69},"Massimo Franchi, M.D.",{"name":73,"affiliation":5,"role":63},"Antonella Cromi, M.D.",[75,79],{"name":62,"role":76,"phone":77,"phoneExt":25,"email":78},"CONTACT","+39 329 6279579","antoniosimone.lagana@asst-settelaghi.it",{"name":65,"role":76,"phone":80,"phoneExt":25,"email":81},"+39 347 0782287","simone.garzon@univr.it",{"type":63,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Antonio Simone Laganà","Principal Investigator",[86],{"name":87,"class":6},"Universita di Verona","100330707",false,"NCT03585738","Effects of Oral Inositol Supplementation on Obstetrics Outcomes in PCOS Women","Effects of Oral Inositol Supplementation on Obstetrics Outcomes in Polycystic Ovary Syndrome Women After Spontaneous Conception","IPOSI-1","Inclusion Criteria:\n\n* Pregnancy spontaneously conceived in women with PCOS diagnosed by Rotterdam criteria that starts oral supplementation before conception.\n\nExclusion Criteria:\n\n* Any kwon pre-pregnancy disease.\n* Any other pharmacological, non-pharmacological or nutraceutical treatment (beside oral folic acid supplementation) more than 3 months before the enrollment (wash-out period) or during the trial, or until the development or pregnancy-induced\u002Frelated diseases requiring pharmacological treatments.",true,"FEMALE","18 Years","40 Years",{"count":100,"type":101},80,"ESTIMATED","INTERVENTIONAL",[104],"NA","Polycystic ovarian syndrome (PCOS) is a heterogeneous, multifaceted and complex disorder characterized by insulin resistance (IR), hyperinsulinemia, and hyperandrogenism leading ovarian disfunction and infertility. Given the central pathogenic role of IR in the endocrine, reproductive, and metabolic disturbances of PCOS, several pharmacological and non-pharmacological approaches have been proposed to counteract the hyper insulinemic IR typical of the syndrome. Two Inositol stereoisomers, Myo-Inositol (MI) and D-chiro-inositol (DCI), captured the attention of researchers for their insulin-sensitizing actions, which configure them as proper candidates for the treatment of PCOS.\n\nVery few studies reported on spontaneous clinical pregnancy rates, none were powered for this outcome, and none reported on the clinically relevant outcome of live birth. Therefore, data about clinical pregnancy rate, live birth rate, and miscarriage rate comparing inositols with placebo are limited.\n\nNevertheless, regarding infertility the primary outcomes that should be considered are clinical pregnancy rate, miscarriage rate and live birth rate. Although many studies showed improved hormonal and metabolic profile and improved ovulation rate and higher quality and number of oocyte retrieved in Assisted Reproductive Technology (ART) in PCOS women after inositols administration, data about clinical pregnancy rate, live birth rate, and miscarriage rate are limited with several concerns regarding interpretation of the studies.\n\nFurthermore, independently by the effect on PCOS related infertility, few data are available about the role of inositol on obstetrics outcomes of pregnancies conceived after treatment with inositol and\u002For orally supplemented during pregnancy. Considering that the combination of MI and DCI alleviate many of the metabolic dysregulations typical of PCOS thanks to insulin-sensitizing actions, it is plausible consider a beneficial effects on pregnancy complications such as gestational diabetes and preeclampsia.",[107],"Polycystic Ovary Syndrome",[109,110,111,112,113,114],"Inositol","Polycystic ovarian syndrome","Pregnancy","Obstetrics outcomes","Gestational diabetes","Preeclampsia","NOT_YET_RECRUITING","2020-11-03",{"date":118,"type":119},"2020-11-05","ACTUAL",{"date":121,"type":101},"2022-01-01",{"date":123,"type":101},"2026-12-31",{"name":5,"class":6}]